Skip to main content

Table 4 Changes of the echocardiographic findings in patients without cancer therapeutics-related cardiac dysfunction

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

 

Baseline

After chemotherapy

After trastuzumab therapy

LVEDVI (mL/m2)

56.5 ± 9.9

55.9 ± 10.2

55.7 ± 10.3

LVESVI (mL/m2)

20.3 ± 4.6

20.0 ± 5.1

20.2 ± 5.7

LVEF (%)

63.9 ± 5.9

64.2 ± 6.7

63.8 ± 7.3

LVGLS (%)

−22.2 ± 2.2

−20.2 ± 2.2*

−17.8 ± 2.3†‡

E (cm/sec)

62.7 ± 7.7

61.4 ± 11.6

59.2 ± 11.8

e’ (cm/sec)

8.3 ± 1.8

8.3 ± 1.7

7.9 ± 1.7

s’ (cm/sec)

7.4 ± 1.0

7.3 ± 1.0

7.3 ± 1.1

E/e’

7.7 ± 1.2

7.6 ± 1.5

7.7 ± 1.8

LAVI (mL/m2)

26.0 ± 3.9

26.1 ± 4.1

26.7 ± 4.0

PALS (%)

33.8 ± 5.6

30.9 ± 5.7*

28.0 ± 6.0†‡

LA conduit strain (%)

19.8 ± 3.3

16.6 ± 3.0*

15.0 ± 3.2†‡

LA booster strain (%)

14.0 ± 2.3

14.3 ± 2.7

13.0 ± 2.8†‡

RVSP (mmHg)

32.0 ± 7.3

30.8 ± 7.7

29.2 ± 8.1

  1. LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E: early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure. *: p < 0.05 between baseline and after chemotherapy, †: p < 0.05 between after chemotherapy and after trastuzumab therapy, ‡: p < 0.05 between baseline and after trastuzumab therapy